Middle East & Africa Generic Drugs Market Analysis and Forecast by Size, Share, Growth, Trends 2031

The Middle East & Africa generic drugs market size is expected to reach US$ 35,795.50 million by 2031 from US$ 28,684.12 million in 2024. The market is estimated to record a CAGR of 3.2% from 2025 to 2031.

Executive Summary and Middle East & Africa Generic Drugs Market Analysis:

The Middle East and Africa (MEA) generic drugs market is experiencing significant growth driven by improved healthcare infrastructure, rising demand for affordable treatments, and an increasing prevalence of chronic diseases such as diabetes, cardiovascular disorders, cancer, and infectious diseases, including malaria, HIV/AIDS, and tuberculosis. Countries such as Saudi Arabia, the UAE, and South Africa are witnessing heightened demand for generic drugs due to the aging population and rising life expectancy, as per the Ageing in the Middle-East and North Africa, with the elderly expected to form the largest age group by 2050 in MENA. Government initiatives promoting cost-effective healthcare solutions, centralized drug procurement, and price control policies are supporting generic drug adoption across the region. Local pharmaceutical manufacturing is expanding in countries including Egypt, Jordan, and South Africa, helping reduce import dependency and enhance regional drug security. International collaborations and public-private partnerships are further fueling innovation and the production of complex generics and biosimilars, positioning MEA as a key region for utilizing generic pharmaceuticals. The growing awareness about preventive healthcare and the increasing number of health insurance schemes are contributing to higher accessibility of medications. Regulatory reforms and faster drug approval processes are enabling quicker market entry for generic drug producers. Companies are also investing in digital transformation, logistics infrastructure, and cold chain networks to improve last-mile delivery and product quality.

Middle East & Africa Generic Drugs Market: Strategic Insights

Middle East & Africa Generic Drugs Market Segmentation Analysis:

Key segments that contributed to the derivation of the Middle East & Africa generic drugs market analysis are molecule type, indication, type, and distribution channel.

• Based on molecule type, the Middle East & Africa generic drugs market is segmented into antidepressants, antihistamines, analgesics, antibiotics, antivirals, diuretics, and others. The antibiotics segment held the largest share of the market in 2024.

• By indication, the Middle East & Africa generic drugs market is segmented into metabolic diseases, cancer, immunology, respiratory disorder, cardiovascular disorder, neurology disorder, rare diseases, and others. The cancer segment held the largest share of the market in 2024.

• Based on type, the Middle East & Africa generic drugs market is bifurcated into prescription and OTC drugs. The prescription segment held a larger share of the market in 2024.

• By indication, the Middle East & Africa generic drugs market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the market in 2024.

Middle East & Africa Generic Drugs Market Players Density: Understanding Its Impact on Business Dynamics

The Middle East & Africa Generic Drugs Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Middle East & Africa Generic Drugs Market Outlook

According to Living Media India Limited 2025, the expiration of patents on branded drugs significantly drives the pharmaceutical generic drug market. Generic manufacturers can produce and sell bioequivalent versions at significantly lower prices after the patent expiry, creating vast market opportunities. For instance, in 2025-26, key drugs such as Keytruda (developed by Merck for cancer immunotherapy), which generated over US$ 25 billion in sales in 2024, and Ozempic (produced by Novo Nordisk for diabetes and anti-obesity treatment), are set to lose their patents. This initiative will develop new opportunities for generic pharmaceuticals and biosimilars. Other high-revenue drugs, such as Eliquis (Bristol-Myers Squibb's blood thinner) and Cosentyx (Novartis' immunology drug), will face similar patent expirations, further expanding the opportunity for generics.

Several blockbuster drugs are expected to lose their patents in 2024, creating even more space for generic alternatives. Notable drugs include:

• Abilify Maintaina (Otsuka Pharmaceutical), an injectable antipsychotic with US$ 15.5 billion in sales in 2022, is set to lose its patent by October 2024.

• Xarelto (Janssen Pharmaceuticals), a leading anticoagulant, is scheduled to lose its patent in August 2024.

• Farxiga (AstraZeneca), a blockbuster anti-diabetic drug generating ~US$ 4.3 billion annually, will lose its patent in 2024.

• Lynparza (AstraZeneca), used in cancer treatment, with sales of ~US$ 2.7 billion, is also set to lose its patent in 2024.

• Symbicort (AstraZeneca), a respiratory drug, will lose its patent in November 2024.

• Entresto (Novartis), a heart failure treatment generating US$ 2.5 billion in 2022, will lose its patent in May 2024.

• Latuda (Sunovion Pharmaceuticals), an antipsychotic with US$ 1.8 billion in sales, will lose its patent in February 2024.

• Xifaxan (Salix Pharmaceuticals), a gastrointestinal drug with sales of US$ 1.6 billion, will lose its patent in June 2024.

• Cabometyx (Exelixis), used to treat advanced renal cell carcinoma, will lose its patent in September 2024.

These pharmaceuticals collectively generated substantial global revenue and created opportunities for generic manufacturers to develop more cost-effective alternatives. Between 2023 and 2029, patents for over 100 critical drugs, including cancer, diabetes, and cardiovascular drugs, will expire, accounting for more than US$ 300 billion in global annual sales. This loss of exclusivity will significantly expand the market share for generics and biosimilars, reducing healthcare costs worldwide. The influx of generics is expected to reshape the global pharmaceutical landscape by providing more affordable treatment options.

The expiration of patents for high-revenue drugs is anticipated to drive a shift in market dynamics, increasing the affordability and accessibility of healthcare. According to The Indian Express Ltd., 2025, the expiration of patents for these blockbuster drugs will create a surge in generics and biosimilars, providing a substantial growth opportunity for generic drug manufacturers.

Middle East & Africa Generic Drugs Market Country Insights

Based on country, the Middle East & Africa generic drugs market comprises Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. South Africa held the largest share in 2024.

South Africa's generic drugs market is witnessing significant momentum, driven by structural reforms in healthcare, government initiatives, and the need for affordable medication. With a GDP of USUS$ 377.78 billion in 2023, healthcare represented approximately 8.5% of the national GDP-marking it as the second-largest share among sectors. The country is investing in healthcare infrastructure to address key health challenges such as HIV/AIDS, tuberculosis, cancer, and other non-communicable diseases. As per the International Trade Administration (ITA), total prescription drug sales in South Africa amounted to USUS$ 4.514 billion in 2022, of which generic drugs accounted for USUS$ 2.059 billion, indicating a preference for cost-effective treatment options. South Africa's public healthcare system serves nearly 80% of the population, and generics play a vital role in expanding access to essential medicines amid budget constraints. The local market is supported by government-led initiatives such as the National Health Insurance (NHI) scheme, which promotes the use of generics to reduce pharmaceutical expenditure. According to GLOBOCAN 2022 data, 120,226 new cancer cases and 69,874 cancer-related deaths were recorded, underscoring the urgent need for enhanced therapeutic access. The prevalence of chronic diseases such as diabetes and cardiovascular disorders is rising, driven by lifestyle changes and urbanization. In response, South Africa is fostering local pharmaceutical manufacturing, offering incentives to generic drug producers, and simplifying regulatory approval through agencies such as SAHPRA (South African Health Products Regulatory Authority). International pharmaceutical companies are also partnering with local players to boost generic drug availability and reduce import dependency.

Middle East & Africa Generic Drugs Market Company Profiles

Some of the key players operating in the market include Teva Pharmaceutical Industries Ltd, Viatris Inc, Dr. Reddy's Laboratories Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, AbbVie Inc, AstraZeneca Plc, Sanofi SA, Aurobindo Pharma Ltd, and Glenmark Pharmaceuticals Ltd, among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Middle East & Africa Generic Drugs Market Research Methodology:

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations.

• Industry trade journals and other relevant publications.

• Government documents, statistical databases, and market reports.

• News articles, press releases, and webcasts specific to companies operating in the market.

Note:

All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research.

• Enhance the expertise and market understanding of the analysis team.

• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects.

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, business development managers, market intelligence managers, and national sales managers

• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise